"Coal India Aims Rs 40,000-Rs 50,000 Crore Capex In Next 4-5 Years": Chairman
State-run Coal India on Wednesday said that the company is aiming at investing Rs 40,000-50,000 crore as capital expenditure in the next 4-5 years. The Rs 17,000-crore capital expenditure for the current fiscal is "on track", said Coal India's chairman Pramod Agrawal, according to news agency PTI. He also highlighted that the price revision is "inevitable" and may happen soon.
"We have spent Rs 7,000 crore capex so far and our Rs 17,000-crore target for the current fiscal is on track. We will invest around Rs 40,000-50,000 crore in the next 4-5 years. Most of the incremental capex will go into coal production and evacuation'', he said.
On the mismatch between EBITDA (earnings before interest, taxes, depreciation, and amortisation) and the increased capex of the miner, the chairman said that the mining industry is not like any manufacturing entity in which an increase in capital expenses will translate into higher EBITDA.
''We have to carry out such expenditure to maintain production. Since last year only, we have invested heavily in production and evacuation," said Mr Agrawal.
The world's largest coal producing company said that the capital expenditure plan will not be affected due to a fall in receivables as it has "enough cash flow" to manage the investments. As of October 2021, the receivables of the coal refiner were at Rs 12,000 crore, down from Rs 19,000 crore in March 2021.
On Wednesday, November 24, shares of Coal India settled 1.86 per cent higher at Rs 159.10 apiece on the BSE. Coal India opened on the BSE at Rs 158.50, registering an intra day high of Rs 161.60 and an intra day low of Rs 155.65, throughout the trading session today.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.